Biological Mechanism(s) Underpinning the Association between Antipsychotic Drugs and Weight Gain.

antipsychotics bipolar disorder lipid metabolism mental disorders metabolic syndrome neuroscience psychiatry schizophrenia weight gain

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
10 Sep 2021
Historique:
received: 28 07 2021
revised: 04 09 2021
accepted: 08 09 2021
entrez: 28 9 2021
pubmed: 29 9 2021
medline: 29 9 2021
Statut: epublish

Résumé

Weight gain and consequent metabolic alterations are common side-effects of many antipsychotic drugs. Interestingly, several studies have suggested that improvement in symptoms and adverse metabolic effects are correlated. We used next generation sequencing data from NT-2 (human neuronal) cells treated with aripiprazole, amisulpride, risperidone, quetiapine, clozapine, or vehicle control, and compared with the Pillinger P-score (ranked from 0 to 1, indicating greater increase in weight gain and related metabolic parameters) to identify the genes most associated with the drugs' propensity to cause weight gain. The top 500 genes ranked for their correlation with the drugs' propensity to cause weight gain were subjected to pathway analysis using DAVID (NIH). We further investigated transcription factors (TFs) that are more likely to regulate the genes involved in these processes using the prediction tool of key TFs from TRRUST. The results suggest an enrichment for genes involved in lipid biosynthesis and metabolism, which are of interest for mechanisms underpinning weight-gain. The list of genes involved in the lipid pathways that correlated with weight gain was enriched for genes transcriptionally regulated by

Identifiants

pubmed: 34575210
pii: jcm10184095
doi: 10.3390/jcm10184095
pmc: PMC8467356
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : National Health and Medical Research Council
ID : GNT1078928
Organisme : National Health and Medical Research Council
ID : GNT1153607

Références

Pharmgenomics Pers Med. 2011;4:83-93
pubmed: 23226055
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Neuropsychopharmacology. 2010 Jun;35(7):1520-30
pubmed: 20336059
J Clin Psychiatry. 2021 May 11;82(3):
pubmed: 34004092
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Mol Psychiatry. 2009 Mar;14(3):308-17
pubmed: 18195716
World J Biol Psychiatry. 2016 Sep;17(6):467-74
pubmed: 26982812
Sci Rep. 2017 Sep 7;7(1):10901
pubmed: 28883496
Lancet Psychiatry. 2020 Jan;7(1):64-77
pubmed: 31860457
Eur Neuropsychopharmacol. 2017 Jun;27(6):589-598
pubmed: 27492885
World Psychiatry. 2017 Jun;16(2):163-180
pubmed: 28498599
Pharmacogenomics J. 2005;5(5):298-304
pubmed: 16027736
CNS Drugs. 2008;22(6):477-95
pubmed: 18484791
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Schizophr Res. 2010 Nov;123(2-3):225-33
pubmed: 20692814
J Child Adolesc Psychopharmacol. 2021 Jun;31(5):364-375
pubmed: 34143682
Prog Neuropsychopharmacol Biol Psychiatry. 2021 Mar 8;105:110130
pubmed: 33045322
Neuropharmacology. 2001 Aug;41(2):200-9
pubmed: 11489456
Front Biosci (Landmark Ed). 2011 Jan 01;16:49-60
pubmed: 21196158
Schizophr Bull. 2016 Nov;42(6):1418-1437
pubmed: 27217270
Front Pharmacol. 2021 Jul 14;12:711940
pubmed: 34335273
Transl Psychiatry. 2021 Jun 30;11(1):365
pubmed: 34226491
Lancet. 2013 Sep 14;382(9896):951-62
pubmed: 23810019
Pharmacol Res. 2007 Sep;56(3):202-8
pubmed: 17651982
Neurosci Biobehav Rev. 2017 Apr;75:91-103
pubmed: 28143762
Expert Opin Drug Saf. 2019 Dec;18(12):1149-1160
pubmed: 31564170
Int J Mol Sci. 2021 Jul 02;22(13):
pubmed: 34281223
Nucleic Acids Res. 2018 Jan 4;46(D1):D380-D386
pubmed: 29087512
Eur Psychiatry. 2011 Apr;26(3):144-58
pubmed: 21295450
Prog Neuropsychopharmacol Biol Psychiatry. 2015 Jan 2;56:136-41
pubmed: 25201120
Schizophr Res. 2007 Jul;93(1-3):13-22
pubmed: 17407804
BMC Neurosci. 2006 Oct 20;7:69
pubmed: 17052361
PLoS One. 2021 Feb 17;16(2):e0244944
pubmed: 33596211
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3456-9
pubmed: 17360666
World J Biol Psychiatry. 2020 Dec;21(10):775-783
pubmed: 29956574
Obesity (Silver Spring). 2021 Feb;29(2):265-273
pubmed: 33491309
Int J Neuropsychopharmacol. 2008 Feb;11(1):49-61
pubmed: 17708778

Auteurs

Bruna Panizzutti (B)

Institute for Innovation in Physical and Mental Health and Clinical Translation, IMPACT, School of Medicine, Deakin University, Geelong 3220, Australia.

Chiara C Bortolasci (CC)

Institute for Innovation in Physical and Mental Health and Clinical Translation, IMPACT, School of Medicine, Deakin University, Geelong 3220, Australia.

Briana Spolding (B)

Institute for Innovation in Physical and Mental Health and Clinical Translation, IMPACT, School of Medicine, Deakin University, Geelong 3220, Australia.

Srisaiyini Kidnapillai (S)

Institute for Innovation in Physical and Mental Health and Clinical Translation, IMPACT, School of Medicine, Deakin University, Geelong 3220, Australia.

Timothy Connor (T)

Institute for Innovation in Physical and Mental Health and Clinical Translation, IMPACT, School of Medicine, Deakin University, Geelong 3220, Australia.

Mark F Richardson (MF)

Genomics Centre, School of Life and Environmental Sciences, Deakin University, Geelong 3220, Australia.

Trang T T Truong (TTT)

Institute for Innovation in Physical and Mental Health and Clinical Translation, IMPACT, School of Medicine, Deakin University, Geelong 3220, Australia.

Zoe S J Liu (ZSJ)

Institute for Innovation in Physical and Mental Health and Clinical Translation, IMPACT, School of Medicine, Deakin University, Geelong 3220, Australia.

Laura Gray (L)

Institute for Innovation in Physical and Mental Health and Clinical Translation, IMPACT, School of Medicine, Deakin University, Geelong 3220, Australia.
Florey Institute for Neuroscience and Mental Health, University of Melbourne, Parkville 3052, Australia.

Jee Hyun Kim (JH)

Institute for Innovation in Physical and Mental Health and Clinical Translation, IMPACT, School of Medicine, Deakin University, Geelong 3220, Australia.
Florey Institute for Neuroscience and Mental Health, University of Melbourne, Parkville 3052, Australia.

Olivia M Dean (OM)

Institute for Innovation in Physical and Mental Health and Clinical Translation, IMPACT, School of Medicine, Deakin University, Geelong 3220, Australia.
Florey Institute for Neuroscience and Mental Health, University of Melbourne, Parkville 3052, Australia.

Michael Berk (M)

Institute for Innovation in Physical and Mental Health and Clinical Translation, IMPACT, School of Medicine, Deakin University, Geelong 3220, Australia.
Florey Institute for Neuroscience and Mental Health, University of Melbourne, Parkville 3052, Australia.
Department of Psychiatry, Royal Melbourne Hospital, University of Melbourne, Parkville 3052, Australia.
Centre of Youth Mental Health, University of Melbourne, Parkville 3052, Australia.
Orygen Youth Health Research Centre, Parkville 3052, Australia.

Ken Walder (K)

Institute for Innovation in Physical and Mental Health and Clinical Translation, IMPACT, School of Medicine, Deakin University, Geelong 3220, Australia.

Classifications MeSH